Burden of fungal infections in Senegal

Badiane, Aïda Sadikh; Ndiaye, Daouda; Denning, David W.

doi:10.1111/myc.12381

Cited by 30 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 21,073,423 cases are estimated for just 16 countries, with majority of these cases in sub-Saharan Africa amongst school children ( Table 9 ). The highest estimated cases were from Nigeria (15,581,400 cases) [ 62 ] followed by Kenya with 1,712,676 cases [ 75 ], with Senegal, Uganda and Tanzania reporting 1,523,700, 1,300,000 and 420,000 cases respectively [ 78 , 122 , 133 ]. Algeria is the only North Africa country that has estimated the burden of the disease and they reported 4265 cases [ 64 ].…”

Section: Estimate Precisionmentioning

confidence: 99%

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Bongomin

Gago

Oladele

et al. 2017

JoF

1,830

1,628

View full text Add to dashboard Cite

Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.

show abstract

Section: Estimate Precisionmentioning

confidence: 99%

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Bongomin

Gago

Oladele

et al. 2017

JoF

1,830

1,628

View full text Add to dashboard Cite

show abstract

“…Perhaps an even greater barrier to treatment than both the developing and evolving resistance profiles of A. fumigatus , and the not insignificant side effect profiles of the current treatment modalities, is a lack of education, awareness and resources for treatment of these patients in both the developed and developing world. The Global Action Fund for Fungal Infections (GAFFI) estimates CPA affects over 3 million people worldwide and multiple studies using literature searches and population modelling have identified CPA as a truly global problem spanning continents and differing disease entities [ 2 , 7 , 8 , 21 , 230 , 231 , 232 , 233 , 234 , 235 ]. Much of the population modelling described has been undertaken in the developing world where economies and health infrastructure are poorly developed and the ability to recognise and treat the disease early is limited.…”

Section: Treatments Barriersmentioning

confidence: 99%

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?

Hayes

Frazer

2016

JoF

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is estimated to affect 3 million people worldwide making it an under recognised, but significant health problem across the globe, conferring significant morbidity and mortality. With variable disease forms, high levels of associated respiratory co-morbidity, limited therapeutic options and prolonged treatment strategies, CPA is a challenging disease for both patients and healthcare professionals. CPA can mimic smear-negative tuberculosis (TB), pulmonary histoplasmosis or coccidioidomycosis. Cultures for Aspergillus are usually negative, however, the detection of Aspergillus IgG is a simple and sensitive test widely used in diagnosis. When a fungal ball/aspergilloma is visible radiologically, the diagnosis has been made late. Sometimes weight loss and fatigue are predominant symptoms; pyrexia is rare. Despite the efforts of the mycology community, and significant strides being taken in optimising the care of these patients, much remains to be learnt about this patient population, the disease itself and the best use of available therapies, with the development of new therapies being a key priority. Here, current knowledge and practices are reviewed, and areas of research priority highlighted.

show abstract

“…Faced with these statistics, fungal infections only represent a secondary priority at a national level. However, as already demonstrated in neighbouring countries [ 4 ], the fungal burden of serious fungal infections may be largely underestimated. This is mainly due to the limited access to adequate and reliable diagnostic tests, but also to erroneous presumptive diagnoses in favor of other prevalent infections, as reported for histoplasmosis and tuberculosis in Cameroon [ 5 ].…”

Section: Introductionmentioning

confidence: 98%

Burden of Severe Fungal Infections in Burkina Faso

Bamba¹,

Zida

Sangaré³

et al. 2018

JoF

View full text Add to dashboard Cite

Because of the limited access to more powerful diagnostic tools, there is a paucity of data regarding the burden of fungal infections in Burkina Faso. The aim of this study was to estimate the incidence and prevalence of serious fungal infections in this sub-Saharan country. We primarily used the national demographic data and performed a PubMed search to retrieve all published papers on fungal infections from Burkina Faso and its surrounding West African countries. Considering the prevalence of HIV infection (0.8% of the population) and a 3.4% incidence of cryptococcosis in hospitals, it is estimated that 459 patients per year develop cryptococcosis. For pneumocystosis, it is suggested that 1013 new cases occur every year. Taking into account the local TB frequency (population prevalence at 0.052%), we estimate the prevalence of chronic pulmonary aspergillosis at 1120 cases. Severe forms of asthma with fungal sensitization and allergic bronchopulmonary aspergillosis are estimated to affect 7429 and 5628 cases, respectively. Vulvovaginal candidiasis may affect 179,000 women, and almost 1,000,000 children may suffer from tinea capitis. Globally, we estimate that roughly 1.4 million people in Burkina Faso (7.51% of the population) suffer from a serious fungal infection. These data should be used to drive future epidemiological studies, diagnostic approaches, and therapeutic strategies.

show abstract

Burden of fungal infections in Senegal

Cited by 30 publications

References 30 publications

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?

Burden of Severe Fungal Infections in Burkina Faso

Contact Info

Product

Resources

About